Listed

Ernexa Therapeutics Inc.: Form 10-Q for the period ended Mar 31, 2019

Filed with the SEC on May 14, 2019 and accepted by EDGAR at May 14, 2019, 16:40 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2019-01-01 to 2019-03-31$4.8mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Selling, general and administrative3 months2019-01-01 to 2019-03-31$3.5mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2019-01-01 to 2019-03-31−$217.0kus-gaap:OperatingIncomeLoss
Income tax3 months2019-01-01 to 2019-03-31$11.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2019-01-01 to 2019-03-31−$313.0kus-gaap:NetIncomeLoss
Diluted EPS3 months2019-01-01 to 2019-03-31−$0.11us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2019-01-01 to 2019-03-31$780.0kus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2019-01-01 to 2019-03-31$41.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2019-03-31$2.7mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-03-31$6.2mus-gaap:AssetsCurrent
Total assetsAt period end2019-03-31$16.5mus-gaap:Assets
Current liabilitiesAt period end2019-03-31$4.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-03-31$9.8mus-gaap:Liabilities
Current portion of debtAt period end2019-03-31$1.0mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2019-03-31$6.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-19-007099. Last ingested by Listed: Nov 11, 2026, 02:49 ET. Listed shows no prices and gives no investment advice.